Home › Research › Biomarkers
Advancing Theranostics in Alzheimer Disease: FDA Approval of Amyloid- PET Drugs for Selection of Patients for Amyloid-ߖDirected Therapies and Other Labeling Updates
Hayoung Koo, Venkata Satyanand Mattay, A. Alex Hofling, Sue‐Jane Wang, Daniel M. Krainak, Younsook Kim, Kevin M. Krudys, Teresa Buracchio et al.. Journal of Nuclear Medicine, 2026-02-19
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Theranostics—the use of diagnostic and therapeutic drugs that target the same molecular marker of disease—extends beyond the paradigm of radiopharmaceutical drug pairs used in oncologic settings (e.g., somatostatin receptor subtype 2 and prostate-specific membrane antigen theranostics) to other
What this study adds
Evidence grade: Low
This paper discusses theranostics, the use of diagnostic and therapeutic drugs targeting the same molecular marker, and FDA approval of amyloid PET drugs for selecting patients for amyloid-directed therapies. It is a labeling and regulatory update rather than a study of a new treatment or cure.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Koo, H., Mattay, V. S., Hofling, A. A., Wang, S., Krainak, D. M., Kim, Y., et al. (2026). Advancing Theranostics in Alzheimer Disease: FDA Approval of Amyloid- PET Drugs for Selection of Patients for Amyloid-ߖDirected Therapies and Other Labeling Updates. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.271312
Vancouver
Koo H, Mattay VS, Hofling AA, Wang S, Krainak DM, Kim Y, et al. Advancing Theranostics in Alzheimer Disease: FDA Approval of Amyloid- PET Drugs for Selection of Patients for Amyloid-ߖDirected Therapies and Other Labeling Updates. Journal of Nuclear Medicine. 2026. doi:10.2967/jnumed.125.271312. PMID: 41714121.
BibTeX
@article{koo2026-41714121,
author = {Koo, Hayoung and Mattay, Venkata Satyanand and Hofling, A. Alex and Wang, Sue‐Jane and Krainak, Daniel M. and Kim, Younsook and Krudys, Kevin M. and Buracchio, Teresa and others},
title = {{Advancing Theranostics in Alzheimer Disease: FDA Approval of Amyloid- PET Drugs for Selection of Patients for Amyloid-ߖDirected Therapies and Other Labeling Updates}},
journal = {Journal of Nuclear Medicine},
year = {2026},
doi = {10.2967/jnumed.125.271312},
pmid = {41714121},
url = {https://doi.org/10.2967/jnumed.125.271312}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Theranostics—the use of diagnostic and therapeutic drugs that target the same molecular marker of disease—extends beyond the paradigm of radiopharmaceutical drug pairs used in oncologic settings (e.g., somatostatin receptor subtype 2 and prostate-specific membrane antigen theranostics) to other
Why it matters
This paper discusses theranostics, the use of diagnostic and therapeutic drugs targeting the same molecular marker, and FDA approval of amyloid PET drugs for selecting patients for amyloid-directed therapies. It is a labeling and regulatory update rather than a study of a new treatment or cure.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 31/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Nuclear Medicine) |
| Journal's citation record | 2 / 4 | Journal of Nuclear Medicine: journal h-index 230 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Libero Marzella: h-index 7 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | United States Food and Drug Administration: institution h-index 651 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41714121) |
| Free to read | 2 / 2 | Free to read |
| Total | 31 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.2967/jnumed.125.271312
- PubMed: 41714121
- Original source →
- Free full text: Journal of Nuclear Medicine →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Biomarkers from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.